Bromfenac Ophthalmic Solution 0.09% (Xibrom) for Postoperative Ocular Pain and Inflammation

Ophthalmology

Volumn 114, Issue 9, 2007, Pages

  Donnenfeld, Eric D ^a   Holland, Edward J ^b   Stewart, Robert H ^c   Gow, James A ^d   Grillone, Lisa R ^d  

^a EAR AND THROAT HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Houston Eye Associates   (United States)

^d ISTA Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE BURNING; EYE COLOR; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPHTHALMOSCOPY; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLIT LAMP;

EID: 34548224212     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.12.029     Document Type: Article

References (46)

1. Waterbury L., Kunysz E.A., and Beuerman R. Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing. J Ocul Pharmacol 3 (1987) 43-54
2. Abelson M.B., and Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 38 suppl (1993) 115-132
3. Syed N.A., and Hyndiuk R.A. Infectious conjunctivitis. Infect Dis Clin North Am 6 (1992) 789-805
4. Friedlaender M.H. Corticosteroid therapy of ocular inflammation. Int Ophthalmol Clin 23 (1983) 175-182
5. Gieser D.K., Hodapp E., Goldberg I., et al. Flurbiprofen and intraocular pressure. Ann Ophthalmol 13 (1981) 831-833
6. Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 70 (1963) 482-491
7. Solomon K.D., Turkalj J.W., Whiteside S.B., et al. Topical 0.5% ketorolac vs. 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol 115 (1997) 1119-1122
8. Roberts C.W. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg 22 suppl (1996) 780-787
9. Snyder R.W., Siekert R.W., Schwiegerling J., et al. Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 26 (2000) 1225-1227
10. Nichols J., and Snyder R.W. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol 9 (1998) 40-44
11. Voltaren Ophthalma. [package insert] (2003), Novartis Ophthalmics, Duluth, GA
12. Kraff M.C., Martin R.G., Neumann A.C., and Weinstein A.J. Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. J Cataract Refract Surg 20 (1994) 138-144
13. Acular (2002), Allergan Inc, Irvine, CA [package insert]
14. Flach A.J., Lavelle C.J., Olander K.W., et al. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology 95 (1988) 1279-1284
15. Flach A.J., Dolan B.J., Donahue M.E., et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology 105 (1998) 1775-1779
16. Nevanac (2005), Alcon Laboratories, Fort Worth [package insert]
17. Xibrom (2005), ISTA Pharmaceuticals, Irvine, CA [package insert]
18. Xibrom (2006), ISTA Pharmaceuticals, Inc, Irvine, CA [package insert]
19. Brown H.B., and Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman J.G., Limbird L.E., Molinoff P.B., and Ruddon R.W. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. (1996), McGraw-Hill, New York 141-160
20. Sancilio L.F., Nolan J.C., Wagner L.E., and Ward J.W. The analgesic and antiinflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung 37 (1987) 513-519
21. Walsh D.A., Moran H.W., Shamblee D.A., et al. Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. J Med Chem 27 (1984) 1379-1388
22. Hellberg MR, Graff G, Yanni JM, inventors; Alcon Laboratories, Inc., assignee. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders. US Patent 5 475 034. December 12, 1995.
23. Waterbury L.D., Silliman D., and Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 22 (2006) 1133-1140
24. Kawaguchi T., Kida T., Nemoto S., et al. Effect of bromfenac ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgery [in Japanese]. Nippon Ganka Kiyo 54 (2003) 276-279
25. Ohara K., Ohkubo A., Miyamoto T., et al. Effect of bromfenac sodium on postoperative inflammation [in Japanese]. Jpn J Cataract Refract Surg 18 (2004) 168-173
26. Ohara K., Ohkubo A., Miyamoto T., et al. Prevention of miosis during cataract surgery by topical bromfenac sodium [in Japanese]. Rinsho Ganka 58 (2004) 1325-1328
27. Miyake-Kashima M., Takano Y., Tanaka M., et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol 48 (2004) 587-590
28. Takamatsu F., Shiroyama N., Saito Y., and Ichikawa K. Efficacy and adverse effects of bromfenac sodium following cataract surgery [in Japanese]. Rinsho Ganka 57 (2003) 1233-1237
29. Kitao N., Shimoji H., and Fukuda M. Post-marketing surveillance of bromfenac sodium (Bronuck) ophthalmic solution-use-results surveillance [in Japanese]. Atarashii Ganka 22 (2005) 1299-1308
30. Usui M., and Masuda K. Effect of bromfenac sodium (AHR-10282B) eye drops on anterior uveitis [in Japanese]. Ganka Rinsho Iho 91 (1997) 39-44
31. Bronuck (2003), Senju Pharmaceutical Co, Osaka [package insert]
32. WHO Handbook for Reporting Results of Cancer Treatment (1979), World Health Organization, Geneva 16-21 WHO Offset Publication 48
33. Lan K.K., and DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983) 659-663
34. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
35. Donnenfeld E.D., and Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 46 4 (2006) 21-40
36. Heier J., Cheetham J.K., DeGryse R., et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol 127 (1999) 253-259
37. Solomon K.D., Cheetham J.K., DeGryse R., et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 108 (2001) 331-337
38. Sawa M., Masuda K., Usui M., and Komemushi S. Efficacy of 0.1% bromfenac sodium ophthalmic solution for ocular surface inflammation: a double-masked controlled trial [in Japanese]. Nippon Ganka Kiyo 48 (1997) 717-724
39. Shimizu H., Masuda K., Fukado Y., et al. Clinical effect of bromfenac sodium ophthalmic solution on inflammation following intraocular lens implantation: optimal frequency of instillation [in Japanese]. Atarashii Ganka 14 (1997) 309-316
40. Masuda K., Fukado Y., Shimizu H., et al. Effect of bromfenac sodium ophthalmic solution on inflammation following intraocular lens implantation [in Japanese]. Ganka Rinsho Iho 91 (1997) 45-50
41. Taylor S.A., Galbraith S.M., and Mills R.P. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 18 (2002) 401-409
42. Schenker H., Maloney S., Liss C., et al. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Ther 21 (1999) 138-147
43. Eisen S.A., Miller D.K., Woodward R.S., et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150 (1990) 1881-1884
44. Patel S.C., and Spaeth G.L. Compliance in subjects prescribed eyedrops for glaucoma. Ophthalmic Surg 26 (1995) 233-236
45. Ikeda H., Sato M., Tsukamoto H., et al. Evaluation and multivariate statistical analysis of factors influencing patient adherence to ophthalmic solutions [in Japanese]. Yakugaku Zasshi 121 (2001) 799-806
46. Cha S.H., Lee J.S., Oum B.S., and Kim C.D. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol 32 (2004) 180-184